Previous close | 2.0100 |
Open | 1.9800 |
Bid | 1.8600 x 3200 |
Ask | 1.9400 x 1000 |
Day's range | 1.9200 - 2.0400 |
52-week range | 1.7400 - 6.3100 |
Volume | |
Avg. volume | 2,050,166 |
Market cap | 912.367M |
Beta (5Y monthly) | 1.37 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter (Q4) and full year of fiscal year 2023 (FY2023), which
66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their DNA health profile 34 percent of doctors said they had personally taken a direct-to-consumer genetic health test SUNNYVALE, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) today announced that a new survey, which found that primary care physicians are more and more comfortable discussing genetic testing with
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the fiscal year 2023 (FY2023) fourth quarter and full year after the market closes on Thursday, May 25, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s financial results and report on business progress. The webcast
23andMe+ members can now gain insights on the chronic autoimmune conditionSOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report on lupus, a chronic autoimmune disease that can in some severe cases lead to permanent tissue damage, and may affect the skin, joints, heart, lungs, kidneys, circulating blood cells, or brain. The report, which is powered by data from c
Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategySOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheadin
First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral CD200R1 saturation in patients with advanced solid malignanciesRecommended dose selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a study ORLANDO, Fla., April 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics an
Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell disease Expands existing initiatives between 23andMe and Morehouse School of Medicine to increase equity in genetics and genomics ATLANTA and SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Today, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, Morehouse School of Medicine (MSM),
23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today published its inaugural environmental, social and governance (ESG) report. The report outlines the Company's strategy and initiatives to ensure ethical management, promote a diverse and equitable culture, and implement sustainable business operations. The full report is available to view at LINK.
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customersSOUTH SAN FRANCISCO, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced a collaboration with Novartis Pharmaceuticals Corporation (Novartis) to increase awareness for Lipoprotein(a) (Lp(a)). High levels of Lp(a) are associated with increased risk of heart attack, stro
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presentedSOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610 has been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, Apri
92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture66 percent of doctors say genetic testing could help lead to better outcomes for their patients75 percent of people in the US said they’d be more likely to follow their doctor’s advice if they knew their genetic profile was used to personalize their care SUNNYVALE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- A large percentage of people and doctors in the US say that using genetic testing cou
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, with a mission to help people access, understand and benefit from the human genome, dosed the first patie
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in investor presentations at the following conferences: Citi Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 at 9:30 a.m. ET in New York, NYCowen Health Care Confere
Third quarter revenue grew 18% to $67 million Consumer revenue grew 17% year over year FY2023 financial guidance raised to expected revenue range of $290 to $300 million SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3) of its fiscal year
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2023 (FY2023) third quarter after the market closes on Wednesday, February 8, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss th
-14 percent of those surveyed say they’re stressed, compared to more than 47 percent in 2020-Under 20 percent of those surveyed said COVID-19 would interfere with their traditional holiday plans; down from 62 percent in 2020-However, most respondents still have some concern about their overall health, with 77 percent of those surveyed indicating they still feel some sort of negativity around their health SUNNYVALE, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23an
Second quarter revenue grew 37% to $76 millionConsumer revenue grew 27% year over year due to the addition of telehealth revenueOn track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the second quarter (“Q2”) of its fis
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activitySOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, is presenting a trials-in-progress poster detailing tumor types being evalua
FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for confirmatory testing of the 23andMe resultSOUTH SAN FRANCISCO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported that
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2023 (FY2023) second quarter after the market closes on Monday, November 7, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss th
Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignanciesSOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today announced that it will present a trials-in-progress poster presentation on 23ME-00610, an investigational antibod
Chu brings over two decades of experience in product management, design and strategy, as well as expertise with navigating complex industries Daniel Chu Daniel Chu, Chief Product Officer, 23andMe SUNNYVALE, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today appointed Daniel Chu as Chief Product Officer. Prior to joining 23andMe, Chu served as Chief Product Officer for Waymo, where he launched the world’
First quarter revenue grew 9% to $64.5 millionConsumer revenue grew 17% year over year due to the addition of telehealth revenueOn track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the first quarter (“Q1”) of its fiscal yea
SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2023 (FY2023) first quarter after the market closes on Monday, August 8, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s financial results and report on business progress. The webcast can be accessed on